{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:33:13Z","timestamp":1790530393238,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102125","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:41:45Z","timestamp":1717051305000},"page":"102125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perineural Invasion as a Risk Factor For Soft Tissue Progression in Patients With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Resistance"],"prefix":"10.1016","volume":"22","author":[{"given":"Tao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongnan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengsong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denglong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102125_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8290.CD-12-0262","article-title":"Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention","volume":"3","author":"Jia","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2024.102125_bib0002","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102125_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102125_bib0004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102125_bib0005","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102125_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102125_bib0007","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102125_bib0008","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","article-title":"Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clgc.2024.102125_bib0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/pros.24082","article-title":"Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer","volume":"81","author":"Iwamoto","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2024.102125_bib0010","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/pros.24402","article-title":"Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer","volume":"82","author":"Yang","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2024.102125_bib0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2024.102125_bib0012","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.clgc.2024.102125_bib0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcancer.2020.07.004","article-title":"Prostate cancer liver metastasis: dormancy and resistance to therapy","volume":"71","author":"Ma","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clgc.2024.102125_bib0014","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.eururo.2022.02.006","article-title":"Comparison of typical prostate adenocarcinoma and rare histological variant prostate cancer showed different characteristics and prognosis: a surveillance, epidemiology, and end results database analysis","volume":"82","author":"Zhou","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102125_bib0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of Enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102125_bib0016","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102125_bib0017","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.euf.2016.08.007","article-title":"In men with castration-resistant prostate cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database","volume":"3","author":"Whitney","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2024.102125_bib0018","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41391-021-00486-2","article-title":"Clinicogenomic characterization of prostate cancer liver metastases","volume":"25","author":"Alshalalfa","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2024.102125_bib0019","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.prp.2018.04.015","article-title":"Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer","volume":"214","author":"Sainio","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clgc.2024.102125_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy","volume":"119","author":"Heck","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102125_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2024.102125_bib0022","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clgc.2024.102125_bib0023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2024.102125_bib0024","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102125_bib0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.humpath.2017.06.017","article-title":"Perineural invasion by prostate cancer on MR\/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy","volume":"66","author":"Truong","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2024.102125_bib0026","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1055-9965.EPI-16-0237","article-title":"Perineural invasion and risk of lethal prostate cancer","volume":"26","author":"Zareba","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2024.102125_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188411","article-title":"Nerve input to tumours: pathophysiological consequences of a dynamic relationship","volume":"1874","author":"Hutchings","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.clgc.2024.102125_bib0028","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41585-019-0274-3","article-title":"Tumour innervation and neurosignalling in prostate cancer","volume":"17","author":"March","year":"2020","journal-title":"Nat Rev Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:56:38Z","timestamp":1738565798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S155876732400096X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102125","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perineural Invasion as a Risk Factor For Soft Tissue Progression in Patients With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Resistance","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102125"}}